The New Zealand Ministry of Health will withdraw Avandia from the market due to heart risks. The Avandia recall is scheduled for April 29. Medsafe, the agency in New Zealand that regulates prescription drugs, has determined that Avandia heart risks outweigh the benefits of the
Drug regulators at the U.S. FDA have fallen short of ordering an Avandia recall. The FDA decided in 2010 to allow Avandia to remain on the market with more severe restrictions and stronger warnings. Avandia has been removed from the European market.
Avandia, generic name Rosiglitazone, was approved by the FDA to treat Type 2 diabetes in 1998. Gross annual sales of Avandia in peaked in 2006 at more than $3 billion.
In 2007, a study published in the New England Journal of Medicine found that Avandia heart attack risk was significantly greater than that of other diabetes drugs. The study also found a link between Avandia use and a significantly increased risk of sudden cardiovascular death. In response, the FDA added “black box” warning to Avandia. Drug safety advocates called for an Avandia recall.
Avandia lawsuits were filed across the United States claiming that drug maker GlaxoSmithKline failed to warn diabetes patients and doctors of Avandia heart attack risks. 2011 Avandia settlements have been reached in thousands of cases. 2011 Avandia lawsuits continue to be filed across the United States.
If you or someone you love suffered a heart attack after taking Avandia, you may be entitled to financial compensation and should contact an Avandia attorney right away.
Time is limited to file an Avandia lawsuit.
Act now to start your Avandia settlement claim.
Submit the online attorney contact request form for a free, no-obligation consultation with a top Avandia lawsuit attorney.